GemVax & KAEL Group optimizes clinical development processes with Oracle Argus Cloud

Redwood Shores, Calif.—May 13, 2016: Patient safety is critical when pharmaceutical organizations develop new drug therapies and treatments. At the same, these pharmaceutical companies face pressures to deliver timely products to market and minimize costs. Oracle Health Sciences today announced that GemVax & KAEL Group, a novel therapeutic cancer vaccine company in South Korea, is using Oracle Argus Cloud to make faster, more informed drug safety decisions, while reducing the costs of outsourcing its business to a contract resource organization.

With the domestic launch of a new oncology drug and the upcoming global NDA approval for the drug, GemVax wanted to set up an in-house database to manage and have more control over both its new and existing cases. Previously, GemVax’s pharmacovigilance processes were managed through a global contract resource organization.

Oracle Argus Cloud enables GemVAX to improve its pharmacovigilance efficiency and effectiveness, while reducing the overall cost to manage its system in-house. It will also allow GemVax to create new insight into its safety data collection and case processing, and users can quickly drill down into case details.

“We are committed to developing new cancer therapies that harness the selective power of the immune system that seek out and destroy tumor cells,” said Michelle Kim, GemVax. “We rely on technologies like Oracle Argus Cloud to help ensure that we are making safety decisions, reduce risk and help ensure global compliance, so that we can focus on delivering therapies that will improve the quality of life of patients.”